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INTRODUCTION 1
The discovery of clustered regularly interspaced short palindromic repeat (CRISPR) systems, the 2 elucidation of their function, and their exploitation as genome engineering tools are revolutionizing genetic 3 engineering (1) (2) (3) (4) (5) . Discovered as a form of adaptive immunity in bacteria and archaea, CRISPR systems 4 consist of a series of DNA spacer elements derived from invading plasmids or viruses. Interdigitated among 5 the spacers is a series of direct repeats. Depending on the particular system, these series are transcribed and 6 processed into single spacer/repeat units called crRNAs (CRISPR RNAs). In turn, these crRNAs may interact 7 with other short RNAs (e.g., tracrRNA) and one or more CRISPR-associated (Cas) proteins (e.g., Cas9 of 8
Streptococcus pyogenes), culminating in the assembly of an RNA-guided endonuclease directed at degrading 9 DNA from the offending plasmid or virus. 10
11
As genome engineering tools, the CRISPR-Cas endonucleases serve as instruments for generating DNA 12 double-strand breaks (DSBs) with locus-of-interest specificity, at high frequency, and across a wide variety of 13 strains and organisms (6) . When faced with DSBs, cells of the organism being perturbed respond with one or 14 both of two DNA repair pathways known as the non-homologous end joining (NHEJ) pathway and the 15 homology-directed repair (HDR) pathway (7, 8) . DNA DSBs repaired by the more rapid and error-prone NHEJ 16 pathway are characterized by the deletion or insertion of a small number of nucleotides. As one might expect, 17 these insertion/deletion events (INDELS) within the open reading frame of a protein of interest may lead to the 18 deletion of one or more endogenous amino acids, the insertion of one or more non-native amino acids, 19 premature termination, or frameshift mutations. In each of these instances the modified mutant locus will 20 commonly encode a hypomorphic or null allele of the original gene of interest. 21
22
In contrast, DSBs repaired in the presence of a homologous template (e.g., sister chromatid, donor 23 molecule) may be repaired by HDR (9) . For genetic engineers, this provides the opportunity to introduce 24 precise DNA modifications, created at the laboratory bench, into the organism under investigation, at the site of 25 the DSB. 26
27
For traditional gene-targeting, of the sort in use in the mouse for the past thirty years (10) (11) (12) (13) (14) , the traditional 1 paradigm based on a large body of literature, has been to create plasmid vectors with two homology arms of a 2 few to several kilobase pairs in length to act as donor molecules (15, 16) . These arms are situated within the 3 plasmid so as to flank investigator-altered sequences that will be incorporated into the genome after 4 introduction of the plasmid vector into embryonic stem (ES) cells and HDR. Positive and negative selection 5 cassettes are frequently employed to aid in selecting the rare ES cell clones containing properly integrated 6 sequences. This technique is sufficient for modifying genomic sequence on a scale from one nucleotide to 7 several thousand base pairs. The method may fall short, however, when attempting to alter entire mouse 8 genes that often extend over 10s or 100s of thousands of base pairs. 9
10
In these instances, other genetic engineering technologies are employed including such methods as 11 random transgenesis (17, 18) , targeted transgenesis (19, 20), and recombinase-mediated cassette exchange 12 (RMCE) (21, 22). Each of these methods has its drawbacks as well. For example, random transgenic methods 13 deviate from genome modification at the cognate endogenous locus, sufficing to allow transgenes to integrate 14 randomly (where they are subject to variegated expression). During targeted transgenesis, transgenes may be 15 directed specifically to standardized safe harbor sites to limit this position-effect variegation but even here the 16 transgenes are unlinked to their endogenous cognate genes. Like the related RMCE method, targeted 17 transgenesis may involve the use of antibiotic selection cassettes flanked by recombinase-binding sites. In 18 addition to the added complexity, deleting these selection cassettes requires breeding to specific recombinase-19 expressing mice thereby prolonging strain development (23) (24) (25) (26) alternative, a fact that has opened gene-editing experimentation to a wide variety of strains and a broad range 27 of species from bacteria to humans (6) . However, here again, DNA modifications have generally been limited 28 to physical extents on the order of a few to a few thousand base pairs. Moreover, systematic studies of the 1 effect of homology arm length on CRISPR-associated HDR are lacking. 2 3 Despite the associated uncertainties, as described in the report that follows, we sought to expand the limits 4 of CRISPR knock-in technology. Specifically, we attempted to increase the physical extent to which mouse 5 genomic DNA could be replaced with donor (in this case, human) DNA at an orthologous locus. Driving our 6 efforts was the desire to create a whole animal model that would replace 17 kbp of the mouse Bcl2l11 gene 7
with the corresponding segment of human BCL2L11, including a conditionally removable segment (2.9-kbp) of 8 intron 2, a cryptic human exon immediately 3′ of this, and a native human exon some 20 kbp downstream (28). 9
Using two approaches, we first carried out the replacement by employing a combination of bacterial artificial 10 chromosome (BAC) recombineering, classic ES cell targeting, dual selection, and recombinase-driven cassette 11 removal (hereafter referred to as our traditional approach) (29). In the second approach, we used the same 12 vector (devoid of its selectable marker cassettes), microinjecting it along with CRISPR RNA guides and Cas9 13 into mouse zygotes (hereafter referred to as our CRISPR approach). In both instances we were able to 14 achieve humanization of Bcl2l11 to the extent designed, remove all selection cassettes, and demonstrate the 15 functionality of the conditionally removable, loxP-flanked, 2.9-kbp intronic segment. 16 
17
Our latter result may well represent the largest segment of mouse DNA to be replaced by an orthologous 18 human DNA using a CRISPR-directed approach with zygotic injection, to date. The study offers a proof-of-19 principal demonstration that a minimum of at least 25 kbp of genomic DNA can be effectively humanized in 20 mouse, and provides a foundation for further technical optimization in mouse and specialization for use in other 21 species. 22
23

METHODS 24
Husbandry 25
All mice were obtained from The Jackson Laboratory (Bar Harbor, ME), housed on a bedding of white pine 26 shavings, and fed NIH-31 5K52 (6% fat) diet and acidified water (pH 2.5 to 3.0), ad libitum. All experiments 27 were performed with the approval of The Jackson Laboratory Institutional Animal Care and Use Committee 28 (IACUC) and in compliance with the Guide for the Care and Use of Laboratory Animals (8 th edition) and all 1 applicable laws and regulations. 2 3
Preparation of the Targeting Vectors/Donor Molecules 4
We designed a targeting vector/donor molecule with three objectives in mind -1), to humanize a central 5 segment of the BCL2L11/Bcl2l11 gene; 2), to place selectable markers immediately 5' and 3' of the humanized 6 segment; and 3), to flank a 2,903-bp region within one of the humanized introns with loxP sites in order to 7 model a disease-associated deletion observed in 12% of the East Asian population (28). were then electroporated into the recombinogenic E. coli strain, SW102 (32). 18
19
Segments from the mouse and human BACs were amplified using the oligonucleotides described in Table  20 1, restriction-digested at sites incorporated into the oligonucleotides, gel-purified, and assembled into small 21 plasmid vectors as follows: 22 EcoRI/BamHI fragment of PL452, into a pBluescript II vector (Agilent Technologies, Santa Clara, CA USA) 5 modified to contain an R6K origin of replication (33, 34). This plasmid is named pTLD01. 6 7 Segments CD, EF, GH, and IJ were cloned along with the neomycin resistance gene-(Neo R -) containing 8
EcoRI/BamHI fragment of PL451, into a pBluescript II (Agilent Technologies, Santa Clara, CA USA) vector 9 modified to contain an R6K origin of replication (33, 34). This plasmid is named pTLD02. 10 11 Segments OP, QR, and ST were cloned along with the blasticidin resistance gene-(Bsd R -) containing 12
EcoRI/BamHI fragment of pTLD08 (a PL452 derivative carrying attB, attP, and Bsd R ), into a pBluescript II 13 vector (Agilent Technologies, Santa Clara, CA USA) modified to contain an R6K origin of replication (33, 34). 14 This plasmid is named pTLD03. 15
16
Segments AB and YZ were cloned into a pBR322-based vector along with the negatively selectable 17 thymidine kinase (tk) gene (35, 36). This plasmid is named pTLD11. 18
19
Oligonucleotides used in the construction of donor vectors. Restriction enzyme sites have been incorporated within 11-to 13-base segments of non-homology at the 5' end of each primer.
To begin the assembly of our humanized donor vector proper, pTLD01 was used with standard 1 recombineering approaches to place a loxP-flanked neomycin resistance cassette (Neo R ) just distal to the 2 2,903-bp deletion region in the human BCL2L11-containing BAC (29). After transferring the modified BAC to 3 the Cre-expressing E. coli strain, SW106, the Neo cassette was removed by exposing cells to arabinose, 4 leaving a single loxP site remaining (32). For the purpose of CRISPR/Cas9-based zygotic microinjection, the final Neo R /Bsd R -containing vector 1 (plasmid pTLD15) was electroporated; first, into the FLP-expressing E. coli strain SW105 to remove Neo R 2 (making plasmid pTLD66), and next, into a C31 recombinase-expressing E. coli strain (an SW105 derivative) 3 to remove Bsd R (32). The final vector was named pTLD67. ES+2i medium, karyotyped, further tested for the presence of the puromycin resistance cassette by PCR, and 11 assessed for homology arm, insert, and neomycin resistance cassette count by quantitative PCR. Properly 12 targeted clones were microinjected into 3.5-days post coitum (dpc) blastocysts (see below). 13
CRISPR sgRNA Design and Production 15
For our CRISPR approach, all single-guide RNAs (sgRNAs) were designed using an algorithm available at 16 http://crispr.mit.edu (39). These sgRNAs, shown in Table 2 , were designed along two concepts. In the first, the 17 two highest scoring sgRNAs (one in each direction) within a 250-bp region were selected from both the 5' and 18
3' ends of the 17-kbp segment of the mouse Bcl2l11 segment being replaced. In the second, two internal 19 sgRNAs (one in each direction) closest to each end of the replaced segment were selected regardless of their 20 overall score. Guides were produced according to the method of Briner, et al. (40) . Cas9 mRNA (CRISPR 21 associated protein 9 mRNA, 5-methylcytidine, pseudouridine) was purchased from TriLink Biotechnologies 22 (San Diego, CA). 23 For our traditional approach, properly targeted ES clones were microinjected into 3.5-dpc blastocysts, and 5 the blastocysts transferred to pseudopregnant host dams, by standard techniques (41). The resulting embryos 6
were allowed to go to term; the pups were delivered naturally and reared by the dams until weaning at four 7 weeks of age. 8 9 For our CRISPR approach, microinjection mixes were prepared as shown in Table 3 . Approximately 80 10 C57BL/6NJ zygotes were microinjected (in one to two technical replicates with each microinjection mix 11 described above), transferred to pseudopregnant females by standard techniques, and allowed to go to term 12 where they were reared by the dams until weaning at four weeks of age. 13
14
Four guides were designed at each end of the mouse Bcl2l11 gene segment to be replaced including two (one in each orientation) with the top design score, and two (one in each orientation) located closest to the outermost ends. Potentially chimeric mice, arising from the microinjection of 3.5-dpc blastocysts (traditional approach) or 1-5 celled zygotes (CRISPR approach), and their progeny were genotyped at designed Cas9 binding sites using 6 the oligonucleotide primers described in Table 4 . As shown (See Fig 2) , these primers were used in pairs, in 7 separate PCR reactions designed to amplify DNA across: 1) the Cas9 binding sites of intact (or small INDEL-8 containing) mouse alleles, 2) the mouse/human junctions of humanized alleles (or randomly integrating 9 transgenes), and 3) the breakpoints of any deletion-bearing alleles. 10 11 To show that the human segment of BCL2L11 had replaced its mouse counterpart in the orthologous 16
Bcl2l11 locus, we used genetic mapping to localize the humanized segment of the BCL2L11/Bcl2l11 gene 17
Standard PCR primers were designed to amplify the junctions flanking the original mouse Bcl2l11 allele, the humanized BCL2L11 allele, and the deletion-bearing allele.
(See Fig 3) . Two backcrosses were established using the following approach. First, FVB/NJ females were 1 crossed to C57BL/6NJ males carrying the humanized segment to obtain F1 hybrid (FVBB6NF1/J) progeny. 2 These progeny were then genotyped for the presence of the humanized segment. Males carrying the human 3 sequence (FVBB6NF1/J-BCL2L11) were backcrossed to either FVB/NJ females or C57BL/6NJ females to 4 generate N2 progeny. Following electroporation of the pTLD39 vector into the JM8-A3 line of ES cells and selection on G418, we 20 assayed 89 surviving clones for the presence of the puromycin resistance cassette by PCR. Of these, twenty-21 seven contained the puromycin cassette and were subjected to puromycin selection. Of these, four clones 22 survived and were assessed for homology arm, insert, and neomycin resistance cassette count by quantitative 23 PCR. One clone passed all of these tests for proper targeting of the central human BCL2L11 segment to the 24 endogenous mouse Bcl2l11 gene. ES cells from this clone were microinjected into blastocysts resulting in nine 25
high-quality chimeras. The four highest quality male chimeras were mated to C57BL/6NJ females resulting in 26 two independent instances of germline transmission of the humanized allele. Although presumably identical, 27 independent lines (genetic background: C57BL/6JN) were developed from each instance. Mating males with 28 B6N.Cg-Tg(Sox2-Cre)1Amc/J female mice resulted in progeny in which the loxP-flanked 2.9-kbp human 1 intronic segment was deleted, as designed. 2
CRISPR Approach 4
At term, a total of 94 pups were born; six were stillborn and six did not survive to four weeks of age. Eighty-5 two mice were weaned and distributed among experiments as shown in Table 4 (conducted with a donor DNA concentration equal to that of Experiment 5, i.e., 10 ng/µL) and Experiment 8 (a 10 replicate of Experiment 3) resulted in seven and 21 pups, respectively, suggesting that the lack of pups in 11 Experiments 3 and 5 was due to technical failure rather than anything systematically wrong with the 12 experimental design. 13
14
To genotype these 82 progeny PCR assays were designed to span each of the proximal and distal 15 mouse/human junctions and to span the 17-kbp mouse region to be replaced. The results of these experiments 16 are shown in Table 5 . As noted, PCR assays designed to span each of the proximal and distal mouse/human 17 junctions identified three founders that were positive for both (Experiment 2, guides closest to ends, 1 ng/µL 18 donor DNA; Experiment 6, guides closest to ends, 5 ng/µL donor DNA; and Experiment 7, highest scoring 19 guides, 10 ng/µL donor DNA). PCR assays designed to span the 17-kbp mouse region to be replaced 20 identified two of the three founders described above (Experiment 6, guides closest to ends, 5 ng/µL donor 21 DNA; and Experiment 7, highest scoring guides, 10 ng/µL donor DNA). To further explore the inheritance of these genetic changes, we mated the human insertion/deletion-1 positive P0s from Experiments 2, 6, and 7 to C57BL/6J mice and genotyped their progeny. The results of these 2 analyses are shown in Table 5 . As shown, the human insertion-positive P0 mouse (male) from Experiment 2 3 (guides closest to ends, 1 ng/µL donor DNA) failed to transmit the humanized allele to any of 29 of its N1 4 progeny suggesting that the P0 mouse is mosaic with a germline consisting primarily of unmodified wildtype 5 cells. 6 7 In contrast, the human insertion-and deletion-positive P0 mouse (male) from Experiment 7 (highest scoring 8 guides, 10 ng/µL donor DNA) transmitted its deletion-bearing allele to four of its 21 N1 progeny. This P0 mouse, 9 however, did not transmit the human insertion-bearing allele to any of these 21 mice again suggesting that the 10 P0 mouse is mosaic with a germline consisting of relatively few human insertion-bearing cells. 11 12 Interestingly, the human insertion-and deletion-positive P0 mouse (female) from Experiment 6 (guides 13 closest to ends, 5 ng/µL donor DNA) transmitted either a human insertion-bearing allele or a deletion-bearing 14 allele to all of its 13 N1 progeny, but never both, implying that this animal is breeding as a true heterozygote 15 with a genotype of both human insertion-and deletion-bearing alleles at the Bcl2l11 locus. Subsequent 16 breeding of three select N1 mice (two bearing the human insertion and one bearing the deletion) gave results 17 consistent with Mendelian expectations. Mating males with B6N.Cg-Tg(Sox2-Cre)1Amc/J female mice resulted 18 in progeny in which the loxP-flanked 2.9-kbp human intronic segment was deleted, as designed. 19 20
Genetic mapping 21
We used an outcross-backcross genetic mapping strategy as a means of localizing the insertion site of 22 BAC-derived human BCL2L11 sequences. Twenty-two N2 progeny were analyzed from the C57BL/6NJ X 23 (FVB/NJ X C57BL/6NJ) backcross and twenty-eight progeny from the FVB/NJ X (FVB/NJ X C57BL/6NJ) 24 backcross. Analysis of the data demonstrates strong linkage between the human BCL2L11 segment and 25 several genetic markers on mouse Chromosome 2 (See Fig 3) . In the backcross to C57BL/6NJ, the marker 26 with strongest linkage, marker rs13476756, had a log-odds ratio (LOD) of 6.58 (p<0.004). In the backcross to 27 FVB/NJ, marker rs13476756 had a LOD score of 7.64 (p<0.0004). 28
Analysis of individual haplotypes (specifically, points of recombination in samples 261, 263, 266, 303, and 1 319) further narrows the insertion-critical region to a 45.2-Mbp region from marker rs4223406 (nucleotide 2 113,827,352) to marker rs3689600 (nucleotide 159,014,253) on Mouse Chromosome 2 (GRC38/mm10), which 3 is consistent with integration into the 36,510-bp mouse Bcl2l11 gene that spans from nucleotide 128,126,038 4 to nucleotide 128,162,547. Put another way, this analysis shows that both the mouse Bcl2l11 gene and the 5 engineered human sequences must be colocalized within a region comprising less than 2% of the mouse 6 genome. We conclude that integration of the human sequence has not occurred randomly, but has indeed 7 occurred by homologous recombination as designed. 8 9
DISCUSSION 10
Contemporary CRISPR technology is revolutionizing genetic engineering and has contributed [along with 11 zinc-finger nuclease (ZFN) and transcription activator-like effector nuclease (TALEN) technologies] to the 12 newly emergent field of gene editing (43-56). The greater CRISPR technique is in a period of rapid expansion, 13
its methodology now being applied across dozens of species in thousands of laboratories around the globe. 14 Moreover, the seminal core technology continues to diversify with additional enzymatic reagents, novel 15 applications, and technical improvements under robust investigation. This, in turn, has led to a rapid expansion 16 of CRISPR knowledge and the publication of CRISPR reports and reviews on a daily basis. 17 18 In the experiments reported here, we set out to explore the feasibility of using CRISPR technology to 19 replace large (10s of kbp) segments of the mouse genome with human DNA from orthologous loci. Current 20 CRISPR approaches aimed at knocking experimental DNAs into a locus of interest by homologous 21 recombination have generally involved relatively small genomic expanses from single nucleotides to a few 22 kilobase pairs. Moreover, these experiments routinely make use of long oligonucleotides, or targeting vectors 23 with sub-kilobase homology arms, as donor molecules. Only more rarely are targeting vectors used of the 24 sizes routinely employed in studies involving mouse ES cells. 25 26 In contrast to these common practices, we surmised that experimentally altered DNAs, of 10s to 100s of 27 kilobase pair lengths, might be directed into a locus of interest if the DNA were outfitted with homology arms 28 15-30 times longer than those in common use today. Accordingly, we used a traditional approach with bacterial 1 artificial chromosomes containing both human and mouse genomic DNA to prepare a donor molecule with 25-2 kbp of human BCL2L11 genomic sequence flanked by 15-kbp and 30-kbp mouse homology arms. We have 3 demonstrated by PCR, sequence, and linkage analysis that replacement of a minimum of 25-kbp of mouse 4 genomic DNA can be achieved using human DNA from the corresponding locus. 5
6
Given this proof-of-principle, future studies can now begin to explore questions of efficiency and 7 optimization. In our experiment we performed microinjection into mouse zygotes to see if mice could be 8 recovered, with any degree of humanization of the mouse Bcl2l11 gene, and if these mice were capable of 9 transmitting the humanized allele through the germline to their offspring. These experiments have 10 demonstrated the feasibility of this CRISPR/BAC technology to introduce experimental DNA in a directed 11 fashion to the zygotic genome and the ability of the specifically targeted DNA to be transmitted through the 12 germline to progeny. However, due to the small number of data points in whole animal experiments, one can 13 only speculate on the impact of guide selection and donor DNA concentration variables on overall success 14 rates. 15 16 Among the experiments in which donor DNA was detected in P0 mice (Experiments 2, 6, and 7), DNA 17 donor concentrations of 1, 5, and 10 ng/µL were represented but the resulting mice show varying degrees of 18 mosaicism. In Experiment 2, where donor DNA concentration was at its lowest (1 ng/µL), donor DNA was not 19 detected among N1 progeny (0/50) suggesting that integration of the donor DNA occurred at multicellular stage 20 of embryonic development and that those cells that did acquire the donor DNA did not contribute to the 21 germline at an appreciable level. 22
23
In Experiment 6, where donor DNA concentration was at an intermediate level (5 ng/µL), donor DNA was 24 detected among nearly half of all N1 progeny (14/31) suggesting that integration of the donor DNA occurred at 25 the one-cell (zygotic) stage of embryonic development, that that cell gave rise to all cells of the germline, and 26 that the donor DNA was passed, during meiosis, into half of the population of mature spermatozoa. This result 27 is consistent with our hypothesis that a deletion, of the 17-kbp mouse segment to be replaced, occurred at the 28 Bcl2l11 locus in the homologous chromosome in the zygote, and was transmitted, in repulsion to the DNA 1 insertion, to all remaining progeny (17/17) . This result is entirely congruent with the optimal desired outcome, 2 i.e., where the P0 zygote undergoes biallelic modification, develops into a mouse with no mosaicism, and 3 transmits one or the other variant alleles in equal numbers (50%:50%) to the population of mature 4 spermatozoa. 5
6 In Experiment 7, where donor DNA concentration was at the highest level tested (10 ng/µL), the 17-kbp 7 deletion was detected in only 25% of all N1 progeny (14/56), and the donor DNA, present in the P0 mouse, was 8 not transmitted to the N1 generation at all (0/56). These results can be explained assuming a scenario 9 whereby a deletion occurred in one Bcl2l11 allele, in a single blastomere, at or near the two-cell stage, and that 10 this deletion-bearing cell gave rise to roughly half of the developing premeiotic germline and a fourth of all 11 mature (postmeiotic) germcells. At some later point in blastogenesis, one can hypothesize that an insertion of 12 donor DNA occurred, but in so few cells as to not contribute to the germline in an appreciable way. 13
14
A number of aspects in Experiment 7 may have contributed to its less than optimal result. First, due to its 15 viscosity, a donor DNA preparation with a DNA concentration that is too high may not be efficiently delivered 16 through the microinjection needle to the zygote, or delivered in a form less conducive to promoting Cas9 17 activity and/or HDR. Moreover, the guides designed for this experiment, although designed to have an optimal 18 score, did not have what we surmised to be an optimal position, near the ends of the mouse DNA segment to 19 be replaced. It may be that, in experiments of this type, guide position represents a more significant design 20 parameter than guide score alone. It is interesting to note that, among all experiments using guides designed 21 for high score optimization, only in Experiment 7, where donor DNA concentration was at the highest level 22 tested (10 ng/µL), was any evidence of donor DNA incorporation seen, and even here it was at a level 23 apparently so low in the P0 founder mouse as to not transmit the modified allele to N1 mice. You may recall that, 24 in the previously mentioned Experiment 6, where an optimal result was achieved, donor DNA concentration 25 was only 5 ng/µL. It is entirely possible that the successful result seen in that instance was driven by superiorly 26 performing/positioned (nearest the end) guides even at what could prove to be a suboptimal donor DNA 27 concentration. Comparing Experiment 6 with Experiment 7, it is interesting to note that the experiment with the 28 Schematic showing the organization of genotyping primers. Numbers, primer designation as in Table 4; and haplotype analysis indicate that the BCL2L11 vector's integration has occurred between markers 19 rs4223406 and rs3689600 and its segregation is fully concordant with markers rs13476756 and rs3662211. 20
This result is entirely consistent with integration of the human BCL2L11 segment within the endogenous 21 mouse Bcl2l11 gene as designed. 22
